IP Library Granted Patent US 7,950,396
Granted Patent B2
US 7,950,396 · App. 11/741,604 · Granted May 31, 2011

Treatment for otitis externa

Assignee: Ondine International Holdings Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,950,396
App. No.
11/741,604
Granted
May 31, 2011
Kind
B2
Abstract

The present invention presents devices, kits, systems and methods that can be used to otitis externa. For example, a method of present invention includes applying a photosensitizing composition to treatment site within ear cavity where microbes causing otitis externa are located; inserting at least a portion of a light delivery device into the cavity; and applying light to the treatment site at a wavelength absorbed by the photosensitizing composition so as to inhibit or eliminate the microbes and/or to reduce inflammation at the treatment site but without causing physiological damage to host tissue within the ear cavity; wherein the light is delivered by the light delivery device to the treatment site and the light delivery device is in light communication with a light source via a waveguide.

Claims (26)

1. A method of treating otitis externa comprising:

(a) applying a photosensitizing composition to treatment site within ear cavity where microbes causing otitis externa are located;

(b) inserting at least a portion of a light delivery device into the cavity; and

(c) applying light to the treatment site at a wavelength absorbed by the photosensitizing composition so as to inhibit or eliminate the microbes and/or to reduce inflammation at the treatment site but without causing physiological damage to host tissue within the ear cavity; wherein

(i) the light is delivery by the light delivery device to the treatment site;

(ii) the light delivery device is in light communication with a light source via a waveguide;

(iii) the photosensitizing composition comprises of toluidine blue at a concentration ranges from about 0.001 wt % to about 1 wt %; and

(iv) the wavelength ranges from about 600 nm to 670 nm.

2. The method of claim 1 wherein the photosensitizing composition comprises of toluidine blue at a concentration ranges from about 0.001 wt % to about 0.1 wt %; the wavelength ranges from about 620 nm to about 650 nm and light energy provided by each of the application of light step to the treatment site ranges from about 6 J/cm 2 to about 12J/cm 2 .

3. A method of treating otitis externa comprising;

(a) applying a photosensitizing composition to treatment site within ear cavity where microbes causing otitis externa are located;

(b) inserting at least a portion of a light delivery device into the cavity; and

(c) applying light to the treatment site at a wavelength absorbed by the photosensitizing composition so as to inhibit or eliminate the microbes and/or to reduce inflammation at the treatment site but without causing physiological damage to host tissue within the ear cavity; wherein

(i) the light is delivered by the light delivery device to the, treatment site:

(ii) the light delivery device is light communication with a light source via a waveguide;

(iii) the photosensitizing composition comprises of methylene blue at a concentration ranges from about 0.001 wt % to about 1 wt %; and

(iv)the wavelength ranges from about 650 nm to 680 nm.

4. A method of treating otitis externa comprising:

(a) applying a photosensitizing composition to treatment site within ear cavity where microbes causing otitis externa are located;

(b) inserting at least a of a light deliver device into the cavity; and

(c) applying light to the treatment site at a wavelength absorbed by the photosensitizing composition so as to inhibit or eliminate the microbes and or to reduce inflammation at the treatment site but without causing physiological damage to host tissue within the ear cavity; wherein

(i) the light is delivered by the light delivery device to the treatment site;

(ii) the light delivery device is in light Communication with a light source via a waveguide;

(iii) the photosensitizing composition comprises of methylene blue at a concentration ranges from about 0.001 wt % to about 0.1 wt %;

(iv) the wavelength ranges from about 665 nm to about 675 nm; and

(v) light energy provided by each of the application of light step to the treatment site ranges from about 6J/cm 2 to about 12J/cm 2 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2023
From: ONDINE INTERNATIONAL HOLDINGS LTD.
To: ONDINE INTERNATIONAL AG
Reel/Frame 062430/0914 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2011
From: ONDINE INTERNATIONAL LTD.
To: ONDINE INTERNATIONAL HOLDINGS LTD.
Reel/Frame 026124/0869 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2008
From: LOEBEL, NICHOLAS G; ANDERSEN, ROGER; ROSE, ANDREAS; STREET, CALE; HERR, GUENTER; JOHNSTON, KYLE
To: ONDINE INTERNATIONAL LTD.
Reel/Frame 020978/0450 →
Continuity (3)
Provisional Application 60866897 · Nov 22, 2006
Provisional Application 60796345 · Apr 28, 2006
Related Publication 20080119914A1 · May 22, 2008